Journal of the American Academy of Dermatology
Volume 59, Issue 3 , Pages 418-425, September 2008

A topical antioxidant solution containing vitamins C and E stabilized by ferulic acid provides protection for human skin against damage caused by ultraviolet irradiation

Division of Dermatology, Duke University Medical Center, Durham, North Carolina

Accepted 7 May 2008. published online 07 July 2008.

Background

Skin cancer and photoaging changes result from ultraviolet (UV)-induced oxidative stress. Topical antioxidants may protect skin from these effects.

Objective

We sought to determine whether a stable topical formulation of 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid (CEFer) could protect human skin in vivo from substantial amounts of solar-simulated UV radiation.

Methods

CEFer and its vehicle were applied to separate patches of normal-appearing human skin for 4 days. Each patch was irradiated with solar-simulated UV, 2 to 10 minimal erythema doses, at 2-minimal erythema dose intervals. One day later, skin was evaluated for erythema and sunburn cells, and immunohistochemically for thymine dimers and p53. UV-induced cytokine formation, including interleukin (IL)-1α, IL-6, IL-8, and IL-10, and tumor necrosis factor-α, were evaluated by real-time polymerase chain reaction.

Results

CEFer provided significant and meaningful photoprotection for skin by all methods of evaluation.

Limitations

The number of patients evaluated was relatively small.

Conclusion

CEFer provided substantial UV photoprotection for skin. It is particularly effective for reducing thymine dimer mutations known to be associated with skin cancer. Its mechanism of action is different from sunscreens and would be expected to supplement the sun protection provided by sunscreens.

Abbreviations used: cDNA, complementary DNA, CEFer, 15% L-ascorbic acid, 1% alpha-tocopherol, and 0.5% ferulic acid, IL, interleukin, MED, minimal erythema dose, mRNA, messenger RNA, PBS, phosphate-buffered saline, PCR, polymerase chain reaction, RT, real time, TNF, tumor necrosis factor, UV, ultraviolet

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by a grant from SkinCeuticals-L'Oreal, New York, NY.

 Disclosure: Dr Pinnell is a consultant for SkinCeuticals-L'Oreal. Dr Murray, Mr Burch, Mr Streilein, Ms Iannacchione, and Dr Hall have no conflicts of interest to declare. C E Ferulic is a patented formulation, US Patent No. 7,179,841 issued to SkinCeuticals.

PII: S0190-9622(08)00541-0

doi:10.1016/j.jaad.2008.05.004

Journal of the American Academy of Dermatology
Volume 59, Issue 3 , Pages 418-425, September 2008